PMID- 32391262
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the 
      Third-Line Setting: A Bayesian Network Analysis.
PG  - 513
LID - 10.3389/fonc.2020.00513 [doi]
LID - 513
AB  - Background: Increasing evidences from phase II or III trials have proved that 
      salvage systematic therapy, including chemotherapy, target therapy, or checkpoint 
      inhibitor therapy can prolong survival in patients who do not succeed with second 
      line therapy, yet there are no guidelines for the optimum third-line treatments. 
      To compare the effectiveness and safety of current third-line therapies for 
      metastatic Gastric Cancer (mGC), we conducted this network analysis. Methods: 
      Literature up to Sep 30, 2019 were systematically searched and analyzed by a 
      Bayesian fixed-effect model. Results: This study included seven randomized 
      clinical trails which involved 2,655 patients. It turns out that for overall 
      survival, nivolumab has the highest probability to be the optimal choice for 
      overall survival (OS). For patients with no peritoneal metastases, the network 
      meta-analysis showed that Nivolumab (HR:0.64; 95% CI: 0.48-0.85) and 
      Trifluridine/tipiacil (HR:0.66; 95% CI: 0.51-0.86) were associated with 
      significantly higher improvement in OS than placebo. However, patients with 
      peritoneal metastases could not benefit from nivolumab, ramucirumab, or 
      Trifluridine/tipiacil, when compared with a placebo. For progression-free 
      survival, apatinib (850 mg) was the most likely candidate, followed by 
      ramucirumab. Statistically, Apatinib (850 mg), Trifluridine/tipiacil, and SLC had 
      higher incidences of high-grade adverse events (AEs) than placebo. Conclusion: 
      Our findings demonstrate that nivolumab has the best balance between 
      acceptability and effectiveness in the third line therapy for mGC.
CI  - Copyright (c) 2020 Pan, Zhou, Pan, Luo, Zhang, Yang and Qiu.
FAU - Pan, Wen-Tao
AU  - Pan WT
AD  - State Key Laboratory of Oncology in South China, Department of Experimental 
      Research, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Zhou, Su-Na
AU  - Zhou SN
AD  - State Key Laboratory of Oncology in South China, Department of Experimental 
      Research, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Pan, Meng-Xian
AU  - Pan MX
AD  - State Key Laboratory of Oncology in South China, Department of Experimental 
      Research, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Luo, Qiu-Yun
AU  - Luo QY
AD  - State Key Laboratory of Oncology in South China, Department of Experimental 
      Research, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Zhang, Lin
AU  - Zhang L
AD  - State Key Laboratory of Oncology in South China, Department of Clinical 
      Laboratory, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Yang, Da-Jun
AU  - Yang DJ
AD  - State Key Laboratory of Oncology in South China, Department of Experimental 
      Research, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen 
      University Cancer Center, Guangzhou, China.
FAU - Qiu, Miaozhen
AU  - Qiu M
AD  - State Key Laboratory of Oncology in South China, Department of Medical Oncology, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University 
      Cancer Center, Guangzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20200423
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7191061
OTO - NOTNLM
OT  - Bayesian network analysis
OT  - gastric cancer
OT  - overall survival
OT  - progression free survival
OT  - safety
OT  - systematic therapy
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:01
PMCR- 2020/01/01
CRDT- 2020/05/12 06:00
PHST- 2019/11/01 00:00 [received]
PHST- 2020/03/23 00:00 [accepted]
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.00513 [doi]
PST - epublish
SO  - Front Oncol. 2020 Apr 23;10:513. doi: 10.3389/fonc.2020.00513. eCollection 2020.